Detection of mutations related to approved drugs in solid and liquid biopsies in oncology

SAYENS



15 Décembre 2017

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

CONTEXT

Conventional methods for detecting DNA mutations lack sensitivity and completeness. In addition, the poor quality of the DNA extracted from paraffin biopsies is responsible for 20% of unsuccessful analyses by next-generation sequencing (NGS) using the Amplicon method. We have developed a method to overcome these drawbacks and have applied it to better diagnosis of several cancers and improved theranostics.


DESCRIPTION

The laboratory has developed a next-generation "One Shot" sequencing method based on 11 genes for the detection of mutations related to drugs with a Marketing Authorization (MA) in oncology (for multiple types of cancers).

The accuracy and depth of the analysis provides the ability to detect these mutations, even the rarest, in the circulating DNA of blood plasma.

This technology drastically improves theranostics in the area of oncology and improves the ability of  the oncologists to diagnose the cancer and choose the  therapeutic strategy.

 

COMPETITIVE ADVANTAGES  

  • Analysis on blood samples and solid biopsies
  • 1 single run for 11 genes linked to several MA
  • High accuracy, very low background noise, detection of rare mutations even on degraded DNA
  • Nearly 1 in 2 non-biopsiable patients now benefit from specific treatment
  • Fluidity of analyses on all types of next-generation sequencers

 

APPLICATIONS AND MARKETS

Oncology - Theranostics:

  • Analysis of tumor mutations from DNA of solid biopsies and blood plasmas
  • Therapeutic decision assistance
  • Basic & applied research

 

 DEVELOPMENT STAGE

  • Method validated on 228 patients (165 solid tumors and 63 blood plasmas)
  • +4,000 patients routinely tested in hospital
  • Approximately 1 in 4 patients benefits from a therapeutic improvement compared to gold standards

 

INTELLECTUAL PROPERTY

European patent application submitted on April 11th, 2018

 

TARGET PARTNERSHIP

Patent licensing

 

CONTACT

Ludmila MONTEIRO

Business Development Manager

 +33 6 31 10 21 21

ludmila.monteiro@sayens.fr

Download the offer Download the offer

Newsletter